

CURRICULUM VITAE

Name	Prof. Dr. med. Stefan Leucht
Age/Date of birth	52 years, born 21.3.1967
Nationality	German
Current Position	Head of the Section for Evidence-Based Medicine in Psychiatry and Psychotherapy at the Department of Psychiatry and Psychotherapy, Technical University of Munich (TUM)
University Studies	1986-87: Law, LMU München 1987-93: Medicine, LMU München
Academic Grades	1995 Promotion (Dr. med., TU-München) 2005 Habilitation "Meta-analytic evaluation of atypical antipsychotics" (Vena legendi Psychiatry and Psychotherapy, TU-Munich) 2011 Adjunct Professor (TU-Munich) 2013-2017 Visiting Professor, Kings College London 2013-2014 Visiting Fellow University of Oxford 2014 Dr. h.c. Universität Craiova 2014- Honorary Professor for Evidence-based Psychopharmacological Treatment, University of Aarhus, Denmark 2019-2022 Visiting Professor, Shanghai Mental Health Center, Jiao Tong University School of Medicine
Medical Training and employments	1993–1994 „Doctor in Practice“ Internal Medicine practice in Munich 1994-2006 Doctor in Practice, Resident, Scientific Assistant Doctor, and finally Consultant, Dpt. of Psychiatry and Psychotherapy, TU-Munich 2006 Specialist exam for Psychiatry and Psychotherapy 2009- Deputy Director, Department of Psychiatry and Psychotherapy, TUM
Foreign work positions	2002-2003 Research Associate at The Zucker Hillside Hospital, Albert Einstein College of Medicine, New York 2013-2014 Visiting Professor, Institute of Psychiatry, King's College London and Honorary Fellow University Dept. of Psychiatry Oxford
Awards	2004: American Psychiatric Association Young Minds in Psychiatry Award 2004, 45000 USD 2010: David Sackett Award of the German EBM network 2012: Robert Kerwin Award of the Royal College of Psychiatry 14 Poster awards and travel stipends
Research Topics	The overarching theme is <u>Evidence-based Medicine in Psychiatry</u> - Meta-analysis with most up-to-date methods (incl. pairwise-, network-, individual patient data-, dose response- and diagnostic test meta-analysis and Overviews of Reviews). - Improvement of Meta-analysis Methods - Conduct of Randomised Controlled Studies in Schizophrenia - Development and Evaluation of Guidelines - Improvement of clinical-trial methods (e.g. development of outcomes) - Transfer Evidence-based Findings in Practice - Time Course of antipsychotic drug effect - Pharmacogenetics/individualized Medicine in Psychiatry For details please see publication list.
Relevant International Collaborations	<u>International:</u> University of Illinois at Chicago; King's College London; Hofstra University School of Medicine, New York; University of Oxford; Kyoto University Graduate School of Medicine, Japan; Karolinska Institut, Schweden; Cochrane Schizophrenia Group, Nottingham; School of Social Work, Bar Ilan University, Israel; University of Ioannina, Greece; University of Utrecht, Holland; University of Verona, Italien; Association for the Improvement of Physical Health of the Mentally Ill, Geneva; Universität Amsterdam, Holland; Shanghai Mental Health Center, Jiao Tong University School of Medicine. <u>National:</u> Psychiatrische Klinik der LMU München; Psychiatrie Universität Mainz; Institut für Klinische Chemie der TU-München;

	Elitestudiengang Neurocognitive Psychology, LMU München; Münchner Studienzentrum
Third party funds	<u>Total: 5.094.228 EURO</u> <u>National and European Community: 4.754.500 EURO</u> <u>Companies/Organisations:61.500 EURO</u> <u>Private Donations: 239.725 EUR</u>
Publications Hirsch Index Impact Factor Total Number of Publications (n), Original Publications, Reviews, other Top publications	Hirsch Index (Google Scholar): 88 (11/2019) Impact Factor Total: >1200 2014 and 2015 among the „World’s most influential scientific minds“ and 2014-2017 listed as “Highly cited researcher” by Thomson und Reuter/Web of Science Original publications: n=197 (IF 1360) Reviews: n=53 (IF 270) Editorials/letters: n=52 3 books, 21 book chapters Top publications (more than 10 Impact Factor points): 6x Lancet (4x First author, IF 39), 5x Lancet Psychiatry (IF 11.6), 4x JAMA Psychiatry (IF 13.8), 9x Am J Psychiatry (IF 14.7), 2x Mol Psychiatry (IF 14.9), 1x World Psychiatry (IF20), 1x Arch Gen Psychiatry (IF 13.8)
Editorial Activity	Editor or Editorial Advisor of: Lancet Psychiatry, Schizophrenia Research, Schizophrenia Bulletin, European Neuropsychopharmacology, Acta Psychiatrica Scandinavica, EBMH, Cochrane Schizophrenia Group, International Psychopharmacology, Journal of Clinical Psychopharmacology, Pharmacopsychiatry, European Archives of Psychiatry and Clinical Neuroscience, Journal of Psychiatry and Psychotherapy Research; moreover peer-reviewer for more than 30 medical journals
Teaching	From 2005-2013 responsible for the internal advanced training at the Dept of Psychiatry: Conduct of the following teaching activities: Participation in the main reading psychiatry Psychiatric Practical for medical students Psychiatry for the Advanced Introduction in the methodology of systematic reviews and meta-analyses Workshops in Evidence-based Psychopharmacological Treatment, University of Aarhus
Lectures	Regular speaker at national and international psychiatric conferences
Clinical Experience	Work experience on closed and open psychiatric wards, in a gerontopsychiatric day clinic, outpatient and liason service and in neurology. Training in all major psychiatric forms of treatment including ECT, training in CBT. Several years consultant of a psychiatric ward with a focus on schizophrenia, 4 years consultant of a psychotherapy ward.
Committees and Panels	Head of the Schizophrenie Guideline Group of the CINP, Member of the Guideline Groups Depression, and Schizophrenia of the German Society for Psychiatry and Psychotherapeutics (DGPPN), and of the British Association for Psychopharmacology, Working Group Methodology of clinical psychopharmacological studies of the Arbeitsgemeinschaft für Neuropsychopharmakologie (AGNP), Working Group Methodology of the ECNP, Board Member of the Section for Epidemiology of the Association of European Psychiatrists

Publications in the last 5 years

Aboraya A., Leucht S., et al. (2017). "A novel approach to measuring response and remission in schizophrenia in clinical trials." Schizophr Res 190: 123-128.

Avram M...Leucht S. ... (2019). "Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms." Brain 142(6): 1813-1826.

Bighelli I...., Leucht S. (2018). "Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis." BMC Psychiatry 18(1): 380.

Bighelli I,.... Leucht S. (2018). "Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis." *World Psychiatry* 17(3): 316-329.

Bighelli I,....Leucht S. (2018). "Psychological interventions for positive symptoms in schizophrenia: protocol for a network meta-analysis of randomised controlled trials." *BMJ Open* 8(3): e019280.

Brandl F,Leucht S.... (2019). "Specific Substantial Dysconnectivity in Schizophrenia: A Transdiagnostic Multimodal Meta-analysis of Resting-State Functional and Structural Magnetic Resonance Imaging Studies." *Biol Psychiatry* 85(7): 573-583.

Cabello J,Leucht S.... (2019). "Impact of non-uniform attenuation correction in a dynamic [(18)F]-FDOPA brain PET/MRI study." *EJNMMI Res* 9(1): 77.

Carbon M,Leucht S.... (2018). "Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis." *World Psychiatry* 17(3): 330-340.

Chaimani A. et al. (2017). "Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article." *Evid Based Ment Health* 20(3): 88-94.

Cipriani A,Leucht S.... (2017). "DSM-III-R change in definition might have affected placebo response to antidepressants - Authors' reply." *Lancet Psychiatry* 4(1): 22-23.

Cipriani A,Leucht S,.... (2018). "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis." *Lancet* 391(10128): 1357-1366.

Cipriani A,Leucht S.... (2016). "Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis." *Lancet* 388(10047): 881-890.

Correll C. U.Leucht S (2017). "Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence." *JAMA Psychiatry* 74(7): 675-684.

Czerwensky F,Leucht S,.... (2015). "CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations." *Ther Drug Monit* 37(2): 152-160.

Dazzan P,Leucht S,.... (2015). "Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research." *Schizophr Bull* 41(3): 574-583.

Dimitrakopoulou V,Leucht S,.... (2015). "Accounting for uncertainty due to 'last observation carried forward' outcome imputation in a meta-analysis model." *Stat Med* 34(5): 742-752.

Dold M,Leucht S. (2015). "Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders." *Cochrane Database Syst Rev* 1: CD009831.

Dold M,Leucht S. (2016). "Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials." *World J Biol Psychiatry* 17(3): 210-220.

Drake R. J,Leucht S,.... (2015). "Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention." *Schizophr Bull* 41(3): 584-596.

Efthimiou O,Leucht S,.... (2017). "Combining randomized and non-randomized evidence in network meta-analysis." *Stat Med* 36(8): 1210-1226.

Efthimiou O,Leucht S,.... (2017). "Alpha Markov model for longitudinal studies with incomplete dichotomous outcomes." *Pharm Stat* 16(2): 122-132.

Fleiner T,Leucht S,.... (2017). "Effects of Short-Term Exercise Interventions on Behavioral and Psychological Symptoms in Patients with Dementia: A Systematic Review." *J Alzheimers Dis* 55(4): 1583-1594.

Furukawa T. A,Leucht S,.... (2016). "Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies." *Lancet Psychiatry* 3(11): 1059-1066.

Furukawa T. A,Leucht S,.... (2019). "Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis." *Lancet Psychiatry* 6(7): 601-609.

Furukawa T. A,Leucht S,.... (2018). "Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy." *Evid Based Ment Health* 21(1): 1-3.

Furukawa T. A,Leucht S. (2015). "Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies." *JAMA Psychiatry* 72(1): 14-21.

Furukawa T. A,Leucht S,.... (2018). "Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis." *Acta Psychiatr Scand* 137(6): 450-458.

Furukawa T. A,Leucht S,.... (2016). "Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review." *BMC Res Notes* 9: 218.

Furukawa T. A,Leucht S,.... (2019). "Translating the BDI and BDI-II into the HAMD and vice versa with equipercetile linking." *Epidemiol Psychiatr Sci*: 1-13.

Furukawa T. A,Leucht S,.... (2016). "Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis." *BMJ Open* 6(7): e010919.

Galling B,Leucht S,.... (2017). "Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis." *World Psychiatry* 16(1): 77-89.

Hartung B,Leucht S. (2015). "Perphenazine for schizophrenia." *Cochrane Database Syst Rev*(3): CD003443.

Hayasaka Y,Leucht S. (2015). "Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials." *J Affect Disord* 180: 179-184.

Heilbronner U,Leucht S. (2016). "The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects." *Harv Rev Psychiatry* 24(2): 118-128.

Helfer B,Leucht S. (2015). "Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination." *BMC Med* 13: 82.

Helfer B,Leucht S. (2016). "Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis." *Am J Psychiatry* 173(9): 876-886.

Heres S. ,...Leucht S. (2016). "The SWITCH study: rationale and design of the trial." *Eur Arch Psychiatry Clin Neurosci* 266(6): 513-521.

Huhn M. ,...Leucht S. (2019). "Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis." *Lancet* 394(10202): 939-951.

Kahn R. S. ,...Leucht S. ,... (2018). "Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study." *Lancet Psychiatry* 5(10): 797-807.

Kambeitz J. ,...Leucht S. ,... (2015). "Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies." *Neuropsychopharmacology* 40(7): 1742-1751.

Kishimoto T. ,...Leucht S. ,... (2018). "Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies." *Schizophr Bull* 44(3): 603-619.

Koutsouleris N. ,...Leucht S. ,... (2016). "Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach." *Lancet Psychiatry* 3(10): 935-946.

Krause M. ,...Leucht S. (2019). "Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis." *Eur Neuropsychopharmacol* 29(9): 1003-1022.

Krause M. ,...Leucht S. (2019). "Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis." *Eur Neuropsychopharmacol* 29(1): 32-45.

Krause M. ,...Leucht S. (2018). "Antipsychotic drugs for elderly patients with schizophrenia: A systematic review and meta-analysis." *Eur Neuropsychopharmacol* 28(12): 1360-1370.

Krause M. ,...Leucht S. (2018). "Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis." *Eur Neuropsychopharmacol* 28(6): 659-674.

Krause M. ,...Leucht S. (2018). "Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis." *Eur Arch Psychiatry Clin Neurosci* 268(7): 625-639.

Lepping P. ,...Leucht S. (2017). "Clinical relevance of findings in trials of CBT for depression." *Eur Psychiatry* 45: 207-211.

Leucht S. (2018). "Is there compelling evidence that schizophrenia long-term treatment guidelines should be changed?" *World Psychiatry* 17(2): 166-167.

Leucht S. ,... (2019). "Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia." *Neuropsychopharmacology* 44(9): 1589-1596.

Leucht S. et al. (2016). "Network meta-analyses should be the highest level of evidence in treatment guidelines." *Eur Arch Psychiatry Clin Neurosci* 266(6): 477-480.

Leucht S. et al. (2018). "60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response." *Schizophr Res* 201: 315-323.

Leucht S. et al. (2019). "Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis." *Neuropsychopharmacology* 44(11): 1955-1966.

Leucht S. et al. (2016). "Second-generation antipsychotics and quality of life in schizophrenia." *Lancet Psychiatry* 3(8): 694-695.

Leucht S. et al. (2017). "Do antipsychotic drugs lose their efficacy for relapse prevention over time?" *Br J Psychiatry* 211(3): 127-129.

Leucht S. et al. (2017). "Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry." *Lancet* 389(10074): 1077-1078.

Leucht S. et al. (2018). "Enthusiasm and Skepticism About Using National Registers to Analyze Psychotropic Drug Outcomes." *JAMA Psychiatry* 75(4): 314-315.

Leucht S. et al. (2017). "What does the MADRS mean? Equipercntile linking with the CGI using a company database of mirtazapine studies." *J Affect Disord* 210: 287-293.

Leucht S. et al. (2018). "Translating the HAM-D into the MADRS and vice versa with equipercntile linking." *J Affect Disord* 226: 326-331.

Leucht S. et al. (2015). "Lithium for schizophrenia." *Cochrane Database Syst Rev*(10): CD003834.

Leucht S. et al. (2015). "How effective are common medications: a perspective based on meta-analyses of major drugs." *BMC Med* 13: 253.

Leucht S. et al. (2017). "Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors." *Am J Psychiatry* 174(10): 927-942.

Leucht S. et al. (2018). "Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?" *Eur Arch Psychiatry Clin Neurosci* 268(7): 621-623.

Leucht S. et al. (2016). "Dose Equivalents for Antipsychotic Drugs: The DDD Method." *Schizophr Bull* 42 Suppl 1: S90-94.

Leucht S. et al. (2015). "Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method." *Schizophr Bull* 41(6): 1397-1402.

Leucht S. et al. (2015). "The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics." *Schizophr Bull* 41(3): 549-558.

Levine S. Z. ,...Leucht S. (2015). "Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia." *Schizophr Res* 164(1-3): 122-126.

Levine S. Z. ,...Leucht S. (2016). "Initial severity and efficacy of risperidone in autism: Results from the RUPP trial." *Eur Psychiatry* 32: 16-20.

Levine S. Z. ,...Leucht S. (2016). "Identifying a system of predominant negative symptoms: Network analysis of three randomized clinical trials." *Schizophr Res* 178(1-3): 17-22.

Maijer K,Leucht S,.... (2018). "Auditory hallucinations across the lifespan: a systematic review and meta-analysis." *Psychol Med* 48(6): 879-888.

Martinuzzi E,Leucht S,.... (2019). "Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study." *Transl Psychiatry* 9(1): 20.

Mavridis D,Leucht S,.... (2016). "Publication bias and small-study effects magnified effectiveness of antipsychotics but their relative ranking remained invariant." *J Clin Epidemiol* 69: 161-169.

McKenna P,Leucht S,.... (2019). "The controversy about cognitive behavioural therapy for schizophrenia." *World Psychiatry* 18(2): 235-236.

Nielsen R. E,Leucht S,.... (2015). "Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials." *Acta Psychiatr Scand* 131(3): 185-196.

Noma H,Leucht S,.... (2019). "Efficient two-step multivariate random effects meta-analysis of individual participant data for longitudinal clinical trials using mixed effects models." *BMC Med Res Methodol* 19(1): 33.

Okhuijsen-Pfeifer C,Leucht S,.... (2018). "Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis." *Acta Psychiatr Scand* 138(4): 281-288.

Prosser A. et al. (2016). "Authors' reply." *Br J Psychiatry* 209(2): 171-172.

Prosser A,Leucht S,.... (2016). "Biological v. psychosocial treatments: a myth about pharmacotherapy v. psychotherapy." *Br J Psychiatry* 208(4): 309-311.

Rothe P. H,Leucht S. (2018). "Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method." *Schizophr Res* 193: 23-28.

Samara M, Leucht S. (2017). "Clozapine in treatment-resistant schizophrenia." *Br J Psychiatry* 210(4): 299.

Samara M. T,Leucht S. (2016). "Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis." *JAMA Psychiatry* 73(3): 199-210.

Samara M. T,Leucht S. (2017). "Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies." *Lancet Psychiatry* 4(11): 859-867.

Samara M. T,Leucht S,.... (2018). "Increasing antipsychotic dose for non response in schizophrenia." *Cochrane Database Syst Rev* 5: CD011883.

Samara M. T,Leucht S. (2018). "Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia." *Cochrane Database Syst Rev* 5: CD011884.

Samara M. T,Leucht S. (2015). "Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review." *Am J Psychiatry* 172(7): 617-629.

Samara M. T. et al. (2016). "Use of Clozapine in Schizophrenia-Reply." *JAMA Psychiatry* 73(10): 1098-1099.

Samara M. T,Leucht S. (2019). "How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials." *Schizophr Bull* 45(3): 639-646.

Schmidt-Kraepelin C,Leucht S,.... (2019). "A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design." *Eur Arch Psychiatry Clin Neurosci*.

Schneider-Thoma J,Leucht S. (2019). "Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis." *Lancet Psychiatry* 6(9): 753-765.

Schneider-Thoma J,Leucht S,.... (2018). "Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials." *Lancet Psychiatry* 5(8): 653-663.

Schooler N. R,Leucht S,.... (2015). "Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms." *Schizophr Res* 162(1-3): 169-174.

Schreier S,Leucht S,.... (2017). "The Prevalence of Mental Illness in Homeless People in Germany." *Dtsch Arztebl Int* 114(40): 665-672.

Schroder C,Leucht S,.... (2019). "Fat Mass and Obesity-Related Gene Variants rs9939609 and rs7185735 are Associated with Second-Generation Antipsychotic-Induced Weight Gain." *Pharmacopsychiatry* 52(1): 16-23.

Siafis S,Leucht S,.... (2019). "Antipsychotic drugs v. barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis." *Psychol Med*: 1-12.

Smith R. C,Leucht S,.... (2019). "Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis." *Psychopharmacology (Berl)* 236(2): 545-559.

Wang Y,Leucht S,.... (2016). "Valproate for schizophrenia." *Cochrane Database Syst Rev* 11: CD004028.

Winkelbeiner S,Leucht S,.... (2019). "Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders: A Meta-analysis." *JAMA Psychiatry*.

Wolf A,Leucht S,.... (2017). "Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials." *Eur Arch Psychiatry Clin Neurosci* 267(3): 187-198.

Zhou X,Leucht S,.... (2017). "Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis." *BMJ Open* 7(8): e016608.

Zhu Y,Leucht S,.... (2017). "Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses." *Lancet Psychiatry* 4(9): 694-705.

Zhu Y,Leucht S,.... (2017). "How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis." *Eur Neuropsychopharmacol* 27(9): 835-844.

Munich, 13th November 2019